tetano
Editor, Senior Moderator
Sci Adv
. 2022 May 13;8(19):eabn7424.
doi: 10.1126/sciadv.abn7424. Epub 2022 May 13.
Detecting anti-SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion
Fernanda Ludolf[SUP] 1 [/SUP], Fernanda F Ramos[SUP] 1 [/SUP], Flávia F Bagno[SUP] 2 3 [/SUP], João A Oliveira-da-Silva[SUP] 1 [/SUP], Thiago A R Reis[SUP] 1 [/SUP], Myron Christodoulides[SUP] 4 [/SUP], Paula F Vassallo[SUP] 5 [/SUP], Cecilia G Ravetti[SUP] 6 [/SUP], Vandack Nobre[SUP] 1 6 [/SUP], Flavio G da Fonseca[SUP] 2 3 [/SUP], Eduardo A F Coelho[SUP] 1 7 [/SUP]
Affiliations
Abstract
Serum-based ELISA (enzyme-linked immunosorbent assay) has been widely used to detect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, to date, no study has investigated patient urine as a biological sample to detect SARS-CoV-2 virus-specific antibodies. An in-house urine-based ELISA was developed using recombinant SARS-CoV-2 nucleocapsid protein. The presence of SARS-CoV-2 antibodies in urine was established, with 94% sensitivity and 100% specificity for the detection of anti-SARS-CoV-2 antibodies with the urine-based ELISA and 88% sensitivity and 100% specificity with a paired serum-based ELISA. The urine-based ELISA that detects anti-SARS-CoV-2 antibodies is a noninvasive method with potential application as a facile COVID-19 immunodiagnostic platform, which can be used to report the extent of exposure at the population level and/or to assess the risk of infection at the individual level.
. 2022 May 13;8(19):eabn7424.
doi: 10.1126/sciadv.abn7424. Epub 2022 May 13.
Detecting anti-SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion
Fernanda Ludolf[SUP] 1 [/SUP], Fernanda F Ramos[SUP] 1 [/SUP], Flávia F Bagno[SUP] 2 3 [/SUP], João A Oliveira-da-Silva[SUP] 1 [/SUP], Thiago A R Reis[SUP] 1 [/SUP], Myron Christodoulides[SUP] 4 [/SUP], Paula F Vassallo[SUP] 5 [/SUP], Cecilia G Ravetti[SUP] 6 [/SUP], Vandack Nobre[SUP] 1 6 [/SUP], Flavio G da Fonseca[SUP] 2 3 [/SUP], Eduardo A F Coelho[SUP] 1 7 [/SUP]
Affiliations
- PMID: 35559681
- DOI: 10.1126/sciadv.abn7424
Abstract
Serum-based ELISA (enzyme-linked immunosorbent assay) has been widely used to detect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, to date, no study has investigated patient urine as a biological sample to detect SARS-CoV-2 virus-specific antibodies. An in-house urine-based ELISA was developed using recombinant SARS-CoV-2 nucleocapsid protein. The presence of SARS-CoV-2 antibodies in urine was established, with 94% sensitivity and 100% specificity for the detection of anti-SARS-CoV-2 antibodies with the urine-based ELISA and 88% sensitivity and 100% specificity with a paired serum-based ELISA. The urine-based ELISA that detects anti-SARS-CoV-2 antibodies is a noninvasive method with potential application as a facile COVID-19 immunodiagnostic platform, which can be used to report the extent of exposure at the population level and/or to assess the risk of infection at the individual level.